EFFECT OF PREDATED VACCINATION AND CHINESE HERBAL ADJUVANT RABBIT HEMORRHAGIC DISEASE VACCINE ON IMMUNE RESPONSE IN YOUNG RABBITS



Similar documents
NCL Method ITA-6. Leukocyte Proliferation Assay

CMP Antibody Production Service

ELISA BIO 110 Lab 1. Immunity and Disease

02/08/ Background. Outline

STANDARD OPERATING PROCEDURE

Development and Evaluation of a Simple Latex Agglutination Test for the Detection of Pig Antibodies Against Human T-cell

Chapter 18: Applications of Immunology

Chapter 3. Immunity and how vaccines work

VETERINARY SERVICES MEMORANDUM NO

Peptide Antibody Production

QED Bioscience Inc. Revision 05/04/11 ADVANCED ANTIBODY TECHNOLOGIES

Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods

(From the Department of Bacteriology, Preventive Medicine and Public Health, School o] Medicine, Howard University, Washington, D. C.

Focus on Preventing Disease. keeping an eye on a healthy bottom line. Cattle Industry

Standard Operating Procedure (SOP)

Immunological differences between layer- and broiler-type chickens

EVALUATION OF DARK FIELD MICROSCOPY, ISOLATION AND MICROSCOPIC AGGLUTINATION TEST FOR THE DIAGNOSIS OF CANINE LEPTOSPIROSIS

In-vitro Effect of Acanthopanax senticosus Polysaccharide on Cultured Blood Lymphocyte Proliferation and Signal Molecules in Pigs

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and

SEROLOGICAL SERVICE IN POULTRY INDUSTRY

A Microfluidic Chemiluminescence Immunoassay for Measurement of Testosterone in Serum and Urine

Principles of Vaccination

Item 2 Guidelines for the Production of Polyclonal and Monoclonal Antibodies in Rodents and Rabbits

Comparing the Tube and Gel Techniques for ABO Antibody Titration, as Performed in Three European Centers 林 良 豐

POLYCLONAL ANTIBODY DEVELOPMENT

TABLE OF CONTENT. Page ACKNOWLEDGEMENTS. iii ENGLISH ABSTRACT THAI ABSTRACT. vii LIST OF TABLES LIST OF FIGURES. xvi ABBREVIATIONS.

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

ALLERGENIC EXTRACT. Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE. U.S. Government License No.

Don t gamble on your HERD S health.

Montanide TM adjuvants for stimulation of cellular immune response in FMD vaccines

低 剂 量 辐 射 对 脐 血 T 淋 巴 细 胞 膜 分 子 表 达 的 影 响 EFFECT OF LOW DOSE IRRADIATION ON EXPRESSION OF MEMBRANE MOLECULES OF T LYMPHOCYTES IN CORD BLOOD

Biopharmaceutical Process Evaluated for Viral Clearance

CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS

CFSE Cell Division Assay Kit

竞 争 性 分 析 Epitope Mapping 实 验 方 法

Dot Blot Analysis. Teacher s Guidebook. (Cat. # BE 502) think proteins! think G-Biosciences

OBTAINING MONOCLONAL ANTIBODIES TO EPITOPES OF IVERMECTIN

Why use passive immunity?

Diagnostic Testing and Strategies for BVDV

STANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA

EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL

International Beryllium Conference, Montreal, Canada March 10, 2005

Custom Antibodies Services. GeneCust Europe. GeneCust Europe

Topic: Serological reactions: the purpose and a principle of reactions. Agglutination test. Precipitation test. CFT, IFT, ELISA, RIA.

4A. Types of Laboratory Tests Available and Specimens Required. Three main types of laboratory tests are used for diagnosing CHIK: virus

NCL Method ITA-14. Analysis of Nanoparticle Effects on Maturation of Monocyte Derived Dendritic Cells In Vitro

QuickTiter Hepatitis B Surface Antigen (HBsAg) ELISA Kit

Mouse IFN-gamma ELISpot Kit

Professional Biological Company Since 1923

STANDARD OPERATING PROCEDURE

Report of the Veal Calf Vaccination Study with Rispoval IntraNasal (Zoetis)

Principles of Vaccination

Immunity and how vaccines work

SOP 001: POLYCLONAL ANTIBODY PRODUCTION IN RABBITS

Monoclonal Antibodies Production for Quantification of Ochratoxin A in Feedstuffs by Enzyme-Linked Immunosorbent Assay

LAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)

TECHNICAL REPORT STUDY CHEMICAL PROPERTIES OF RATTAN SHOOT FROM PLANTATION IN THAILAND

How To Use An Antibody

Title: Mapping T cell epitopes in PCV2 capsid protein - NPB # Date Submitted:

MTT Cell Proliferation Assay

Anti-Zona Pellucida Antibody Latex Agglutination Test

Generation of EBV-immortalized B cell lines

Control of Newcastle and Infectious Bursal diseases in Poultry: Vaccines, Vaccination and Bio security

From Biology to Discovery

lung cancer targeted photodynamic therapy and imaging

HBV Quantitative Real Time PCR Kit

Custom Polyclonal Anti-Peptide Antibody, Brochure

DIAGNOSTIC TEST OF BOVINE TUBERCULOSIS

Antigens & Antibodies II. Polyclonal antibodies vs Monoclonal antibodies

CONTENT. Chapter 1 Review of Literature. List of figures. List of tables

RSV F Recombinant Nanoparticle Vaccine: Summary of Clinical Data

Some Immunological Test. Presented by Alaa Faeiz Ashwaaq Dyaa Aseel Abd AL-Razaq Supervised by D.Feras

1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.

Aviva Systems Biology

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

FMD vaccines and vaccination in India; Production, use and quality. V.A.Srinivasan Research Director Indian Immunologicals Limited Hyderabad

The Body s Defenses CHAPTER 24

BD Pharmingen. Apoptosis, DNA Damage and Cell Proliferation Kit. Technical Data Sheet. Product Information. Description. Material Number: Size:

Essentials in Immunology Prof. R. Manjunath Department of Biochemistry Indian Institute of Science, Bangalore

The Evaluation of Interferon-beta Levels in HPV-positive Cervical Cancer Cell Lines

Human Peripheral Blood Mononuclear Cell (PBMC) Manual

AlphaLISA Human Insulin kit

Protocol for Preparation of Cell-Free Stocks of TCLA HIV-1 in Cell Lines (Montefiori Lab) July 2007

Anticancer Effects of and Direction of Research on Hippophae

COMPARATIVE PERFORMANCE OF IN-HOUSE AND COMMERCIALLY AVAILABLE ELISA KITS FOR THE DETECTION OF ANTIBODY AGAINST NEWCASTLE DISEASE VIRUS VACCINE

ArC Amine Reactive Compensation Bead Kit

IgM ANTIBODY CAPTURE ENZYME-LINKED IMMUNOSORBENT ASSAY PROTOCOL

A Guide to Managing Your Biological Waste at the University at Albany

Psychological Stress and Antibody Response to Immunization: A Critical Review of the Human Literature

Fighting the Battles: Conducting a Clinical Assay

Cold Agglutination Titer detecting Cold Reacting Antibodies

QuickTiter FeLV Core Antigen ELISA Kit (FeLV p27)

Guidelines for Monoclonal Antibody Production

EVALUATION OF THE EFFECT OF THE COMPOUND RIBOXYL ON THE ATP LEVEL AND CELLULAR RESPIRATION FROM HUMAN DERMAL FIBROBLASTS

SARS Experiences in China:

Canine Distemper Virus

The clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age.

Viral Safety of Plasma-Derived Products

Chapter 6. Antigen-Antibody Properties 10/3/2012. Antigen-Antibody Interactions: Principles and Applications. Precipitin reactions

RPCI 004 v.002 Staining Procedure For all Directly Conjugated Reagents (Whole Blood Method)

Transcription:

Pathology and Hygiene EFFECT OF PREDATED VACCINATION AND CHINESE HERBAL ADJUVANT RABBIT HEMORRHAGIC DISEASE VACCINE ON IMMUNE RESPONSE IN YOUNG RABBITS Longsheng Yang*, Jiabin Xue, Fang Wang, Yuanliang Hu, Deyun Wang, Weizhong Xu College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China *Corresponding author: gj@caaa.cn, leesinglee@gmail.com ABSTRACT The experiments were conducted to determine effects of precocious vaccination compared to the classical schedule of vaccination and of Chinese herbal adjuvant (CHA) on immune response to vaccine against rabbit hemorrhagic disease (RHD) in young rabbits. In experiment 1, five New Zealand rabbits at 30, 35, 40 or 45 days of age were injected with 3 ml of non-adjuvant inactivated vaccine against RHD, respectively. The results showed that the titer of maternal HI antibody on day 0 in the 35-day-old rabbits was lower than the protective level of 3 log2; while on days 7 to 49 after the vaccination, the antibody titer was higher than 3 log2. In experiment 2, thirty New Zealand rabbits at 35 days of age were randomly assigned to 5 treatment groups, representing inoculation with 3 ml of non-adjuvant RHD vaccine, CHA-RHD vaccine, CHA-HA (half dose antigen of RHD vaccine) RHD vaccine, aluminium adjuvant-containing RHD vaccine, or phosphate-buffered saline (PBS), respectively. The results showed that the CHA promoted (P<0.05) the lymphocyte proliferation on day 7 and enhanced serum antibody titer on day 21. These findings from the two experiments suggested that vaccination could be carried out at 35 days and Chinese herbal adjuvant significantly enhanced the immune response to vaccine against RHD in comparison with aluminium adjuvant. Key words: Rabbit hemorrhagic disease, Chinese herbal adjuvant, Antibody titer, Lymphocyte proliferation. INTRODUCTION Rabbit hemorrhagic disease (RHD) is a fatal disease of rabbits caused by RHD virus. In 1984 at the initial epidemic stages, the virus mainly infected adult rabbits at 3 to 4 months of age (Du et al., 1991; Wang et al., 1988). In China, the first vaccination of the vaccine against RHD is usually at 45 days of age, and secondly at 65 days of age (Wang, 2000). However, in recent years, the susceptible rabbits become younger. Even rabbits younger than one month old could be infected by RHD (Shien et al., 2000; Cooke, 2002; Mikami et al., 1999), thus, a predated vaccination must to be taken to avoid early infection. On the basis of our recent findings of Chinese herbal adjuvant (CHA), we hypothesized that vaccination date could be predated and CHA could enhance immune response to RHD vaccine in young rabbits. This hypothesis was tested in the present study by determining the dynamic changes of serum HI antibody titers after inoculation with the vaccine against RHD in 30-, 35-, 40- or 45-day-old rabbits, and then the dynamic changes of peripheral lymphocyte proliferation and serum HI antibody titers after injection with the RHD vaccine, or mixture of RHD vaccine and CHA or aluminum adjuvant (AA) in 35-day-old rabbits. The main purpose of these experiments is to find an appropriate vaccinating program to protect the young rabbits from the attack of RHD virus. 999

9 th World Rabbit Congress June 10-13, 2008 Verona Italy Vaccine Preparation MATERIALS AND METHODS Inactivated vaccine against RHD (No. 20051201) and AA were supplied by Jiangsu Academy of Agriculture Science. CHA was supplied by Institute of Traditional Chinese Veterinary Medicine of Nanjing Agricultural University, containing astragalus polysaccharides and ginsenosides, the total content of which was 20 mg/ml. CHA-RHD vaccine, AA-RHD vaccine and non-adjuvant RHD vaccine were prepared by mixing 20 ml of the inactivated vaccine with 10 ml CHA, 3 ml AA and 7 ml phosphate-buffered saline (PBS), and 10 ml PBS, respectively, in which the antigen contents were the same. Another CHA-vaccine, containing half dose of antigen named CHA-HA vaccine, was made of 10 ml inactivated vaccine, 10 ml CHA and 10 ml PBS. Reagents RPMI-1640 (GIBCO) supplemented with 100 IU/ml benzyipenicillin, 100 IU/ml streptomycin and 10% fetal bovine serum (FBS) was used. Phytohemagglutinin (PHA, Sigma, No. 051201), as a T-cell mitogen, was dissolved into 0.10 mg/ml with RPMI-1640. Lipopolysaccharide (LPS, Sigma, No. 051201), as a B-cell mitogen, was dissolved into 0.025 mg/ml with RPMI-1640. The 3-(4,5- dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide (MTT, Amresco Co.) was dissolved into 5 mg/ml with calcium and magnesium-free (CMF) PBS, ph 7.4. These reagents were filtered through a 0.22 µm syringe filter. PHA and LPS solution were stored at -20 C, MTT solution at 4 C in dark bottles. Dimethyl sulfoxide (DMSO, No. 050601) was produced by Kemiou Institute of Chemical Engineering in Tianjin. Lymphocytes Separation Medium (No. 060218) was the product of Hua-jing Biostix Shanghai Inc. Positive serum and negative serum for RHD vaccine were supplied by Jiangsu Academy of Agriculture Science. Human O erythrocyte was provided by Centre Hospital of Nanjing Military Area. Animals New Zealand rabbits at 30 to 45 days of age without any vaccination were housed in wire cages (60 100 cm 2 ) in air-conditioned room at 25 C, and fed with the commercial starter diet. The rabbits and diet were provided by Jiangsu Academy of Agriculture Science. Experimental design Five rabbits of each group at 30, 35, 40 or 45 days of age were used in experiment 1, respectively. All the rabbits were inoculated subcutaneously with 3 ml of the non-adjuvant vaccine on neck. On days 0 (before inoculation), 7, 14, 21, 28, 35, 42 and 49 after initiation of the injection, 0.5 ml of blood was sampled from each rabbit for determination of serum HI antibody titers by micro-method (Zhuang et al., 1995). A total of thirty rabbits at 35 days of age were randomly assigned to 5 treatment groups in experiment 2, representing subcutaneous inoculation with 3 ml of the non-adjuvant RHD, CHA-RHD, CHA-HA RHD, AA-RHD vaccines, or PBS, respectively. On days 0 (before inoculation), 7, 14, 21, 35 and 49 after initiation of the inoculation, 0.5 ml blood per rabbit was sampled to determine the serum HI antibody titers. Also, four rabbits from each group were randomly sampled (2 ml blood per rabbit) for assay of T and B lymphocyte proliferation. Serum HI antibody Assay Blood samples were drawn from the auricular vein of rabbits and sera stored at -20 C until analysis for serum HI antibody. The analysis was done following the procedure in Zhuang et al. (1995). The geometric mean titer was expressed as reciprocal log2 values of the highest dilution that displayed HI (Zhuang et al., 1995). 1000

Pathology and Hygiene Peripheral lymphocyte proliferation assay Using the procedure described in Wu et al. (1993) the blood samples were collected and light absorbance was measured with microliter enzyme-linked immunosorbent assay reader (Model DG- 3022, East China Vacuum Tube Manufacturer) at a wave length of 570 nm. Statistical analysis Data are expressed as the mean ± S.D. Duncan s multiple range test was used to analyze the differences among the treatment groups. A P-value of less than 0.05 was taken to indicate statistical significance. RESULTS Changes of serum HI antibody titer in rabbits vaccinated at different ages Dynamic changes of serum HI antibody titer were showed in Figure 1. The maternal antibody titer dropped with the increase of age. In the 30-day-old rabbits, the titers were higher than 3 log2, while in the 35-day-old rabbits, lower than 3 log2. On days 7 to 14 after initiation of the vaccination, the antibody titers in the 30-day-old rabbits were higher than 3 log2, while lower than 1 log2 on day 49. In the 35-, 40- and 45-day-old rabbits, the antibody titers increased gradually from day 7 after initiation of the vaccination, reached peak-value on day 28, and still higher than 3 log2 on day 49, which were higher (P<0.05) compared with the 30-day-old rabbits. Figure 1: Dynamic changes of serum HI antibody titers in rabbits vaccinated at different age (n=5).data at the same time point with different letters (a-c) differ significantly (P<0.05) Changes of serum HI antibody titer in rabbits vaccinated with different vaccines The dynamic changes of serum HI antibody titer in rabbits vaccinated with different vaccines against HRD were listed in Table 1. On day 0 after initiation of the vaccination, the antibody titers were not significant different (P>0.05) among all of the five treatment groups. The titers in the three adjuvant vaccine groups were higher on days 7 (P>0.05) and 14 (P<0.05) compared with the non-adjuvant vaccine group. On days 21, 35 and 49, the titers in the CHA vaccine group were higher (P<0.05) in comparison with the other four groups. On days 14 and 35, the titers in the CHA-HA vaccine group were higher (P<0.05) than that of the non-adjuvant groups. At all time points, there were no significant differences (P>0.05) between the CHA- HA vaccine group and AA-vaccine group, while the titers in the four vaccinated rabbits were higher (P<0.05) compared with the PBS-inoculated rabbits. 1001

9 th World Rabbit Congress June 10-13, 2008 Verona Italy Table 1: The dynamic changes of serum HI antibody titers in rabbits vaccinated with different vaccines against rabbit hemorrhagic disease (log2; n=6) Treatments Day after initiation of the vaccination 0 7 14 21 35 49 Non-adjuvant vaccine 2.50±2.00 3.00±1.29 a 3.50±0.82 b 4.00±0.41 b 3.80±0.58 c 3.50±0.82 b CHA vaccine 2.67±1.15 3.75±0.96 a 4.50±1.29 a 6.00±0.82 a 6.25±0.96 a 6.00±0.82 a CHA-HA vaccine 2.33±1.53 3.25±0.50 a 4.25±0.50 a 4.50±0.41 b 4.50±0.58 b 4.00±0.82 b AA vaccine 2.33±0.58 3.25±1.26 a 4.50±1.29 a 4.50±0.58 b 5.00±0.82 b 3.13±0.25 b PBS 2.30±1.00 1.00±0.82 b 0.67±0.47 c 0.25±0.28 c 0.33±0.47 c 0.25±0.50 c a-c Means ± S.D. within a column with different superscripts differ significantly (P<0.05) AA, aluminium adjuvant; CHA, Chinese herbal adjuvant; HA, half dose of antigen; PBS Table 2: The dynamic changes of peripheral T lymphocyte proliferation in rabbits vaccinated with different vaccines against rabbit hemorrhagic disease (OD 570 ; n=4) Treatments Day after initiation of the vaccination 0 7 14 21 35 49 Non-adjuvant vaccine 0.268±0.017 0.282±0.017b 0.304±0.086 0.304±0.046 0.303±0.089 0.306±0.068 CHA vaccine 0.258±0.043 0.378±0.049a 0.331±0.083 0.325±0.037 0.323±0.069 0.333±0.037 CHA-HA vaccine 0.283±0.063 0.354±0.044a 0.334±0.038 0.324±0.037 0.318±0.088 0.320±0.046 AA vaccine 0.268±0.071 0.375±0.068a 0.341±0.097 0.331±0.088 0.327±0.010 0.325±0.037 PBS 0.292±0.033 0.280±0.034b 0.282±0.026 0.285±0.031 0.288±0.075 0.300±0.079 a-b Means ± S. D. within a column with different superscripts differ significantly (P<0.05). AA, aluminium adjuvant; CHA, Chinese herbal adjuvant; HA, half dose of antigen; PBS Table 3: The dynamic changes of peripheral B lymphocyte proliferation in rabbits vaccinated with different vaccines against rabbit hemorrhagic disease (OD 570 ; n=4) Treatments Day after initiation of the vaccination 0 7 14 21 35 49 Non-adjuvant vaccine 0.234±0.067 0.301±0.081 bc 0.375±0.052 b 0.322±0.042 b 0.306±0.091 ab 0.306±0.054 ab CHA vaccine 0.206±0.062 0.430±0.036 a 0.444±0.042 a 0.390±0.037 a 0.348±0.099 a 0.339±0.064 a CHA-HA vaccine 0.222±0.084 0.308±0.094 bc 0.362±0.055 b 0.346±0.037 b 0.300±0.088 ab 0.299±0.053 ab AA vaccine 0.232±0.062 0.342±0.073 b 0.390±0.020 b 0.340±0.035 b 0.304±0.097 ab 0.292±0.051 ab PBS 0.248±0.124 0.258±0.019 c 0.260±0.012 c 0.270±0.019 c 0.280±0.075 b 0.274±0.057 b a -c Means ± S. D. within a column with different superscripts differ significantly (P<0.05). AA, aluminium adjuvant; CHA, Chinese herbal adjuvant; HA, half dose of antigen; PBS Changes of peripheral T and B lymphocyte proliferation in rabbits vaccinated with different vaccines The dynamic changes of peripheral T lymphocyte proliferation (Table 2) showed that on day 0 after initiation of the vaccination, the OD 570 values were not significant different (P>0.05) among all of the five treatment groups; on day 7, the values in the three adjuvant vaccine groups were higher (P<0.05) compared with the other two groups, and there were no significant differences (P<0.05) among the three adjuvant vaccine groups. The dynamic changes of peripheral B lymphocyte proliferation (Table 3) showed that on day 0 after initiation of the vaccination, there were no significant differences (P<0.05) among the OD 570 values in all of the five treatment groups; the values of CHA vaccine group were higher (P<0.05) compared with the other four groups on days 7, 14 and 21. On days 35 and 49, the values of the CHA vaccine group were higher in comparison with the other three vaccinated groups (P>0.05) and PBS-inoculated groups (P<0.05). DISCUSSION The serum antibody titer is an indicator of humoral immunity. In our previous study, we found that serum antibody titer higher than 3 log2 could provide 100% protection for rabbits from rabbit hemorrhagic disease, 2 log2, only 50%, lower than 2 log2, a little protection. Therefore, 3-4 log2 of antibody titer was called protective antibody titer. The results from the experiment 1 showed that the maternal antibody titers in the 35- to 45-day-old rabbits were lower than the protective titer (3 log2), which were difficult to resist the infection of RHD virus and needed vaccinating. Thus, when the 1002

Pathology and Hygiene inoculation age was predated to 35 days old, the antibody titer increased rapidly, and was higher than 3 log2 for 7 weeks and 4 log2 for 3 weeks after vaccination. In the experiment 2, antibody titers of the three adjuvant vaccine groups were significantly higher compared with the non-adjuvant vaccine group on day 14 after the vaccination. On days 21, 35 and 49, the titers of the CHA vaccine groups were significantly higher in comparison with the non-adjuvant vaccine groups and AA vaccine groups, which suggested that the immune enhancement of CHA was better than AA. Collectively, these findings suggested that the first vaccination of young rabbits should be predated to 35 days of age in order to resist the infection of RHD virus, and the CHA adjuvant could significantly enhance the production of HI antibody against RHD vaccine in the young rabbits. Lymphocytes proliferation is the indicator reflecting the state of cellular immunity in animal body. Our results showed that on day 7 after the vaccination, peripheral T lymphocyte proliferation significantly increased in the CHA- and AA-vaccine groups compared with the other groups. On days 7, 14 and 21 after the vaccination, the proliferation of B lymphocyte in the CHA groups were significantly higher compared with the AA groups, which suggested that the CHA possessed better effect on enhancing the cellular immunity in comparison with the AA, in addition with the low side-effect and resourceful advantages of the CHA, we suggested that the classical adjuvant AA could be replaced by the new adjuvant CHA. CONCLUSIONS In summary, our findings in the present study suggested that the first vaccination in the young rabbits could be predated to 35 day old. Combination of vaccine with CHA could enhance immune response against the RHD in the animals. Nevertheless, comparison of the CHA adjuvant with other commercial classical vaccine (with oil adjuvant for example) should be realized to confirm if the CHA adjuvant could replace the classical adjuvant. REFERENCES Cooke B.D. 2002. Rabbit haemorrhagic disease: Field epidemiology and the management of wild rabbit populations. Rev. Sci. Tech., 2, 347-358. Du N.X., Xu W.Y., Liu S.J., Xu F.N., Yu Y.R., Li R.J. 1991. Studies on rabbit haemorrhagic disease. Sci. Agr. Sinica., 1, 1-10. Mikami O., Park J.H., Kimura T., Ochiai K., Itakura C. 1999. Hepatic lesions in young rabbits experimentally infected with rabbit haemorrhagic disease virus. Res. Vet. Sci., 3, 237-342. Shien J.H., Shieh H.K., Lee L.H. 2000. Experimental infections of rabbits with rabbit haemorrhagic disease virus monitored by polymerase chain reaction. Res. Vet. Sci., 3, 255-259. Wang Q.M. 2000. Discuss of immune procedure of vaccines on rabbits. Chin. J. Rabbit Farming., 4, 30-31. Wang Y.K., Jie C.Y. 1988. Study on a new virus infection in rabbits-rabbit pest. Scientia Agricultura Sinica, 5, 73-79. Wu M.Y., Liu G.Z. 1993. Medicine Immunology. Beijing: China Science and Technology Press, p. 156-159. Zhuang G.H., Zhu G.Q., Zhou J.H. 1995. Primary study on the RHD immune effect of inactivated oil adjuvnt vaccine. Chin. J. Rabbit Farming, 2, 23-24. 1003

9 th World Rabbit Congress June 10-13, 2008 Verona Italy 1004